Leptin, soluble leptin receptor, and free leptin index in patients with metabolic syndrome

Aim. To assess the levels of leptin, its soluble receptor, and index of the formation of free leptin in metabolic syndrome (MS).

Materials and methods. The study included 110 individuals with obesity and overweight. The group 1 consisted of 70 patients with MS (IDF, 2005), the average body mass index (BMI) 38.4 ± 4.4 kg/m2, aged 48.2 ± 2.4 years, with arterial hypertension (AH) 1–2 degree, without regular antihypertensive therapy. Group 2 – "healthy" obesity accounted for 40 patients aged 38.4 ± 6.2 years, BMI 36.0 ± 5.5 kg/m2 without hypertension and metabolic disorders. Group 3 consisted of 30 healthy persons, BMI 27.1 ± 1.3 kg/m2. All patients were evaluated for insulin, HOMA index, leptin, leptin receptor, leptin free index (calculated as the ratio of leptin (ng/ml) to the leptin receptor (ng/ml), multiplied by 100).

Results: In patients with MS as compared to other two groups there were higher levels of HOMA IR index, leptin and free leptin index. Values of leptin receptor in groups 1 and 2 did not differ significantly and were lower than in healthy persons. The free leptin index was significantly higher in MS group relative to the group 2 and 15 times higher than in the healthy individuals. Free leptin index correlated with values of BMI (R = 0.32; p = 0.02), blood pressure (R = 0.3; p = 0.04), uric acid (R = 0.27; p = 0.04), triglycerides (R = 0.42; p = 0.02), index HOMA-IR (R = 0.45; p = 0.02).

Conclusions:

1. Reduction of soluble leptin receptor, depending on the degree of abdominal obesity, may cause progression of leptin resistance in patients with MS.


2. The levels of leptin and soluble leptin receptor appears to have dramatical gender differences.


3. Calculation of free leptin index should be used for the objective evaluation of leptin resistance, regardless of gender, degree of obesity, and other metabolic parameters.

metabolic syndrome, leptin, leptin receptor, free leptin index

1. Завражных Л.А., Смирнова Е.Н.. Значение психологических характеристик пациента для эффективного лечения метаболического синдрома. // Клиницист. – 2011. – Т. 5. – № 3. – С. 49-55. [Zavrazhnykh LA, Smirnova EN. The importance of psychological characteristics of the patient for the effective treatment of metabolic syndrome. The Clinician. 2011;5(3):49-54. (In Russ.)] doi:10.17650/1818-8338-2011-3-49-54

2. Вербовой А.Ф., Митрошина Е.В. Адипокины и сердечно-сосудистая система. // Эндокринология. Новости, мнения, обучение. – 2014. – № 2. – С. 5-7 [Verbovoy AF, Mitroshina EV. Adipokiny i serdechno-sosudistaya sistema. Endokrinologiya. Novosti, mneniya, obuchenie. 2014;2; 5-7 (In Russ.)].

3. Дедов И.И., Мельниченко Г.А., Бутрова С.А.. Жировая ткань как эндокринный орган // Ожирение и метаболизм. – 2006. – Т. 3. – №1. – C. 6-13. [Dedov II, Mel'nichenko GA, Butrova SA. Zhirovaya tkan' kak endokrinnyy organ. Obesity and metabolism. 2006;3(1):6-13. (In Russ.)] doi:10.14341/2071-8713-49375.

4. Коваренко М.А., Руяткина Л.А., Петрищева М.С. и др. Лептин: физиологические и патологические аспекты действия // Вестник НГУ. Серия: Биология, клиническая медицина. – 2003. – Т.1. – № 1. – С. 59-74. [Kovarenko MA, Ruyatkina LA, Petrishcheva MS, et al. Leptin: fiziologicheskie i patologicheskie aspektyi deystviya. Vestnik NGU. Seriya: Biologiya, klinicheskaya meditsina. 2003;1(1):59-74. (In Russ.)]

5. Бунова С.С. Динамика изменений нейрогуморального профиля и формирование метаболических нарушений у больных артериальной гипертензией в зависимости от массы тела. // Вестник Санкт-Петербургского университета; – 2009. –T. 1. – С. 11-18. [Bunova SS. Dinamika izmeneniy neyrogumoralnogo profilya i formirovanie metabolicheskih narusheniy u bolnyih arterialnoy gipertenziey v zavisimosti ot massyi tela. Vestnik Sankt-Peterburgskog ouniversiteta; 2009;1:11-18. (In Russ.)]

6. Беспалова И.Д., Рязанцева Н.В., Калюжин В.В. Гендерные особенности взаимосвязи гормональной активности жировой ткани и провоспалительного статуса при гипертонической болезни с метаболическим синдромом. // Бюллетень сибирской медицины. – 2014. – Т. 5. – С. 12-19. [Bespalova ID., Ryazantseva NV, Kalyuzhin VV. Gender features of interaction hormonal activity adipose tissue and proinflammatory status in hypertension with metabolic syndrome. Bulletin of Siberian Medicine. 2014;13(5):12-19. (In Russ.)] doi:10.20538/1682-0363-2014-5-12-19

7. El-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. Journal of Clinical Investigation. 2000;105(12):1827-1832. doi: 10.1172/jci9842.

8. Myers MG, Cowley MA, Münzberg H. Mechanisms of Leptin Action and Leptin Resistance. Annual Review of Physiology. 2008;70(1):537-556. doi: 10.1146/annurev.physiol.70.113006.100707.

9. Catli G, Anik A, Tuhan HÜ, et al. The relation of leptin and soluble leptin receptor levels with metabolic and clinical parameters in obese and healthy children. Peptides. 2014;56:72-76. doi: 10.1016/j.peptides.2014.03.015.

10. Holm J-C, Gamborg M, Ward LC, et al. Tracking of Leptin, Soluble Leptin Receptor, and the Free Leptin Index during Weight Loss and Regain in Children. Obesity Facts. 2011;4(6):461-468. doi: 10.1159/000335121.

11. Koh KK, Park SM, Quon MJ. Leptin and Cardiovascular Disease: Response to Therapeutic Interventions. Circulation. 2008;117(25):3238-3249. doi: 10.1161/circulationaha.107.741645.

12. Kratzsch J, Lammert A, Bottner A, et al. Circulating Soluble Leptin Receptor and Free Leptin Index during Childhood, Puberty, and Adolescence. The Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4587-4594. doi: 10.1210/jc.2002-020001.

13. Lieb W, Sullivan LM, Harris TB, et al. Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals. Diabetes Care. 2008;32(4):612-616. doi: 10.2337/dc08-1596.

14. Holm J-C, Gamborg M, Ward LC, et al. Tracking of Leptin, Soluble Leptin Receptor, and the Free Leptin Index during Weight Loss and Regain in Children. Obesity Facts. 2011;4(6):461-468. doi: 10.1159/000335121.

15. Owecki M, Nikisch E, Miczke A, et al. Free leptin index as a marker for leptin action in diabetes and obesity: leptin and soluble leptin receptors relationship with HbA1c. Neuro Endocrinol Lett. 2010;31(5):679-683.